Choose wisely: imaging for diagnosis of axial spondyloarthritis
- PMID: 34049855
- PMCID: PMC8762031
- DOI: 10.1136/annrheumdis-2021-220136
Choose wisely: imaging for diagnosis of axial spondyloarthritis
Abstract
Objective: To assess the diagnostic accuracy of radiography (X-ray, XR), CT and MRI of the sacroiliac joints for diagnosis of axial spondyloarthritis (axSpA).
Methods: 163 patients (89 with axSpA; 74 with degenerative conditions) underwent XR, CT and MR. Three blinded experts categorised the imaging findings into axSpA, other diseases or normal in five separate reading rounds (XR, CT, MR, XR +MR, CT +MR). The clinical diagnosis served as reference standard. Sensitivity and specificity for axSpA and inter-rater reliability were compared.
Results: XR showed lower sensitivity (66.3%) than MR (82.0%) and CT (76.4%) and also an inferior specificity of 67.6% vs 86.5% (MR) and 97.3% (CT). XR +MR was similar to MR alone (sensitivity 77.5 %/specificity 87.8%) while CT+MR was superior (75.3 %/97.3%). CT had the best inter-rater reliability (kappa=0.875), followed by MR (0.665) and XR (0.517). XR +MR was similar (0.662) and CT+MR (0.732) superior to MR alone.
Conclusions: XR had inferior diagnostic accuracy and inter-rater reliability compared with cross-sectional imaging. MR alone was similar in diagnostic performance to XR+MR. CT had the best accuracy, strengthening the importance of structural lesions for the differential diagnosis in axSpA.
Keywords: ankylosing; low back pain; magnetic resonance imaging; spondylitis.
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: TD reports an ASAS research grant during the conduct of the study, personal fees from Canon MS, MSD, Roche and Novartis and an institutional grant from Canon MS outside the submitted work. DP reports grants and personal fees from AbbVie, Eli Lilly, MSD, Novartis, Pfizer and personal fees from Bristol-Myers Squibb, Roche, UCB, Biocad, GlaxoSmithKline and Gilead outside the submitted work. KGH reports personal fees from AbbVie, Novartis, Merck and Pfizer outside the submitted work. For the remaining authors none were declared.
Figures
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
